Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	104
Overall Study	STARTED	Relamorelin 10 μg	98
Overall Study	STARTED	Relamorelin 30 μg	109
Overall Study	STARTED	Relamorelin 100 μg	82
Overall Study	Full Analysis Set (FAS)	Placebo	104
Overall Study	Full Analysis Set (FAS)	Relamorelin 10 μg	98
Overall Study	Full Analysis Set (FAS)	Relamorelin 30 μg	109
Overall Study	Full Analysis Set (FAS)	Relamorelin 100 μg	81
Overall Study	COMPLETED	Placebo	92
Overall Study	COMPLETED	Relamorelin 10 μg	86
Overall Study	COMPLETED	Relamorelin 30 μg	93
Overall Study	COMPLETED	Relamorelin 100 μg	63
Overall Study	NOT COMPLETED	Placebo	12
Overall Study	NOT COMPLETED	Relamorelin 10 μg	12
Overall Study	NOT COMPLETED	Relamorelin 30 μg	16
Overall Study	NOT COMPLETED	Relamorelin 100 μg	19

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02357420/flow